Tag: Iksuda
ESMO 2019: Iksuda Therapeutics’ IKS01 Demonstrates Effective Tumor Regression
The first available data on Iksuda Therapeutics' (previously Glythera) lead antibody-drug conjugate, IKS01, has shown significant and effective tumor regression in preclinical models of...